Earnings Preview: VBI Vaccines, Inc. (VBIV) Q2 Earnings Expected to DeclineZacks Investment Research • 07/23/21
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B VaccineBusiness Wire • 07/01/21
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate TrialBenzinga • 06/29/21
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19Business Wire • 06/29/21
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021Business Wire • 06/23/21
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021Business Wire • 06/09/21
VBI Vaccines' Brain Cancer Immunotherapy Gets FDA Fast Track Review; Announces Updated Tumor Response, Overall Survival DataBenzinga • 06/08/21
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBMBusiness Wire • 06/08/21
VBI Vaccines Secures $12M In Second Tranche of Debt Financing With K2 HealthVenturesBenzinga • 05/21/21
VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVenturesBusiness Wire • 05/21/21
VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual MeetingBusiness Wire • 05/20/21
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious DiseasesBenzinga • 05/12/21
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious DiseasesBusiness Wire • 05/12/21
VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 05/10/21
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021Business Wire • 05/03/21
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)Business Wire • 04/28/21
VBI Vaccines to Participate in National Securities Corporation's Biotech Investor SummitBusiness Wire • 04/27/21